Media ReleasesImmutep

View All Immutep News

Immutep Announce Operational Update


  • TACTI-002 patient recruitment update
  • Six patients now enrolled and dosed in INSIGHT-004, 6 mg cohort complete
  • Significant eftilagimod alpha clinical data expected in coming months:
  1. AIPAC Phase II - data expected in Q1 calendar year 2020
  2. TACTI-002 Phase II - data at SITC in Nov 2019 and in Q1 in 2020
  3. TACTI-mel Phase I - final safety data expected in H1 2020
  4. INSIGHT-004 Phase I - initial safety data expected in Q4 calendar year 2019
  • Scale up to 2,000L for commercial manufacturing started
  • Solid financial position following receipt of $7.4m GSK milestone payment, with expected cash runway at least to the end of calendar year 2020, well beyond above data catalysts
For further information please download the attached PDF: Download this document